Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients

被引：0
|
作者：
Mao, Xuehan [1 ,2 ]
Xu, Yan [3 ]
Yan, Yuting [1 ,2 ]
Liu Jiahui [1 ,2 ]
Fan Huishou [1 ,2 ]
Sui Weiwei [1 ,2 ]
Zengjun, Lizengjun [1 ,2 ]
Deng, Shuhui [4 ,5 ]
Yi, Shuhua [1 ,2 ]
Wang, Tingyu [1 ,2 ]
Wang, Qi [6 ]
Liu, Hui-Min [1 ,2 ]
Qiu, Lugui [1 ,2 ]
An, Gang [1 ,2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union, Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union, Blood Dis Hosp, Tianjin, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol & Blood Dis, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[5] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Medi, Iymphoma & Myeloma, Blood Dis Hosp, Tianjin, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
cytogenetic abnormality; myeloma; survival;
D O I：
10.1016/j.clml.2019.09.132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-047
引用
收藏
页码：E83 / E83
页数：1
相关论文
共 50 条
  • [41] High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
    Hagen, Patrick
    Zhang, Jiwang
    Barton, Kevin
    BLOOD CANCER JOURNAL, 2022, 12 (05)
  • [42] High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
    Patrick Hagen
    Jiwang Zhang
    Kevin Barton
    Blood Cancer Journal, 12
  • [43] Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
    Kumar, Shaji
    Fonseca, Rafael
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dingli, David
    Knudson, Ryan A.
    Greenberg, Alexandra
    Russell, Stephen J.
    Zeldenrust, Steven R.
    Lust, John A.
    Kyle, Robert A.
    Bergsagel, Leif
    Rajkumar, S. Vincent
    BLOOD, 2012, 119 (09) : 2100 - 2105
  • [44] Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Insights From a Multicenter Study
    Liang, Dong
    Li, Xiaojin
    Bai, Shenrui
    Wang, Qiaoli
    Zeng, Min
    Feng, Demei
    Lu, Bo
    Li, Xiaoqing
    Sun, Zhiqiang
    Li, Jianyun
    Zhou, Huanhuan
    Zhang, Jialu
    Chen, Xiaoqin
    Xia, Zhongjun
    Liang, Yang
    Wang, Hua
    CANCER MEDICINE, 2024, 13 (20):
  • [45] Anaplastic Multiple Myeloma Is Associated with High-Risk Molecular Cytogenetic Abnormalities
    Kim, D. T.
    Chang, H.
    MODERN PATHOLOGY, 2009, 22 : 271A - 271A
  • [46] Anaplastic Multiple Myeloma Is Associated with High-Risk Molecular Cytogenetic Abnormalities
    Kim, D. T.
    Chang, H.
    LABORATORY INVESTIGATION, 2009, 89 : 271A - 271A
  • [47] Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma
    Derman, Ben A.
    Chernoff, Meytal
    Jakubowiak, Andrzej
    Chiu, Brian C. -H.
    BLOOD, 2019, 134
  • [48] Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients
    Rahman, Raeef L.
    Khaliq, Aroog
    Laharwal, Mehak M.
    Atrash, Shebli
    Mcguirk, Joseph P.
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Abdallah, Al-Ola
    Ahmed, Nausheen
    Mewawalla, Prerna
    Snyder, Jordan
    BLOOD, 2024, 144 : 6953 - 6954
  • [49] Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
    Charalampous, Charalampos
    Goel, Utkarsh
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie
    Gertz, Morie
    Gonsalves, Wilson
    Hayman, Suzanne
    Hobbs, Miriam
    Hwa, Yi Lisa
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, Vincent
    Kumar, Shaji K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : E329 - E335
  • [50] Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
    Callander, Natalie S.
    Silbermann, Rebecca
    Kaufman, Jonathan L.
    Godby, Kelly N.
    Laubach, Jacob
    Schmidt, Timothy M.
    Sborov, Douglas W.
    Medvedova, Eva
    Reeves, Brandi
    Dhakal, Binod
    Rodriguez, Cesar
    Chhabra, Saurabh
    Chari, Ajai
    Bal, Susan
    Anderson, Larry D.
    Dholaria, Bhagirathbhai R.
    Nathwani, Nitya
    Hari, Parameswaran
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Giri, Smith
    Costa, Luciano J.
    Usmani, Saad Z.
    Richardson, Paul G.
    Voorhees, Peter M.
    BLOOD CANCER JOURNAL, 2024, 14 (01)
12345